JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus

Key facts

Sponsor

Jemincare

Principal Investigator

Xiaofeng Zeng

Peking Union Medical College Hospital

Intervention

JMKX000189(drug)

Enrollment

48 enrolled

Eligibility

18-65 years · All sexes

Timeline

2023 – 2025

Study locations (17)

• The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
• Xuanwu Hospital, Capital Medical University, Beijing, Beijing Municipality, China
• Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
• The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
• The First Affiliated Hospital of Henan University of science and Technology, Luoyang, Henan, China
• Xinxiang Central Hospital, Xinxiang, Henan, China
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
• Jiangsu Province Hospital, Nanjing, Jiangsu, China
• Pingxiang People's Hospital, Pingxiang, Jiangxi, China
• China-Japan Union Hospital of Jilin University, Changchun, Jilin, China
• Binzhou Medical University Hospital, Binzhou, Shandong, China
• Qilu Hospital of Shandong University, Jinan, Shandong, China
• Jining First People's Hospital, Jining, Shandong, China
• Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China
• Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
• +2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT07107659
  Safety and Efficacy of ONT01 in Lupus
  Hospital for Special Surgery, New York
• RECRUITINGNANCT07558850
  Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGNCT06948110
  Deciphering the Genetic Architecture of Autoimmune Diseases
  National Human Genome Research Institute (NHGRI)
• RECRUITINGPHASE2NCT07409181
  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
  Boehringer Ingelheim
• RECRUITINGPHASE3NCT07332481
  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
  EMD Serono Research & Development Institute, Inc.
• RECRUITINGEARLY PHASE1NCT07526350
  MTS109 in Patients With Refractory Autoimmune Diseases
  Shanghai Changzheng Hospital
• RECRUITINGEARLY PHASE1NCT07490041
  Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
  The Children's Hospital of Zhejiang University School of Medicine
• RECRUITINGNANCT07470151
  Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

See all trials for Systemic lupus erythematosus →